treatment

Dr. Graubert’s research focuses on the molecular pathogenesis of myeloid leukemias. While at Washington University in St. Louis, he and his colleagues used genome sequencing technology extensively to gain insights into the genetic basis of human cancer and to use this information to improve risk stratification tools and identify targets for novel therapy.  Their group published the first complete genome sequence of a human cancer (

Dr. Amy DeZern is a hematologist and medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and is an Assistant Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine.

Dr. Rossetti earned his Doctor of Osteopathic Medicine degree from the Lake Erie College of Osteopathic Medicine and completed an internship and internal medicine residency at St. Francis Medical Center of Pittsburgh. He did fellowship training in hematology and medical oncology at The Western Pennsylvania Hospital and is board certified in medical oncology and hematology.  He is an assistant professor at the Temple University School of Medicine and an adjunct clinical instructor for the Lake Erie College of Osteopathic Medicine.

Dr. Robert Coleman Lindsley, M.D., PhD. is a physician scientist at Dana-Farber Cancer Institute, specializing in research topics associated with MDS. His career has developed in conjunction with his interest in how disease evolves, and in turn, how new and existing therapies can interrupt the process of disease progression. The

Dr. Becker is pursuing several areas of research investigation, including 1) the mechanism of adhesion mediated